Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1% Market Closed
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Green Cross Corp
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Operating Expenses
-â‚©430.1B
CAGR 3-Years
0%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Celltrion Inc
KRX:068270
Operating Expenses
-â‚©965B
CAGR 3-Years
-39%
CAGR 5-Years
-32%
CAGR 10-Years
-23%
SK Bioscience Co Ltd
KRX:302440
Operating Expenses
-â‚©154.2B
CAGR 3-Years
-39%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Operating Expenses
-â‚©121.9B
CAGR 3-Years
-15%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Operating Expenses
-â‚©115.4B
CAGR 3-Years
-31%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Operating Expenses
-â‚©37.9B
CAGR 3-Years
-20%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Operating Expenses?
Operating Expenses
-430.1B KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Operating Expenses amounts to -430.1B KRW.

What is Green Cross Corp's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-8%

Over the last year, the Operating Expenses growth was 3%.

Back to Top